Evidence map›Paper›PMID 41058143›Full record

ArticleMolecular imaging and radionuclide therapy2025

Büşra Özdemir Günay, Funda Üstün

Abstract read
In one paragraph

Article in Molecular imaging and radionuclide therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Büşra Özdemir GünayGiresun Training and Research Hospital, Clinic of Nuclear Medicine, Giresun, Türkiye.ORCID 0000-0001-8540-0115
Funda ÜstünTrakya University Faculty of Medicine, Department of Nuclear Medicine, Edirne, Türkiye.ORCID 0000-0002-3250-1032

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Contralateral lung parenchymal metastasis (CLM), less common than expected in lung cancer, and its exact mechanism is still unknown. To determine the additional value of Methods: The data were evaluated by comparing the group with CLM and the group without CLM but with distant metastasis to other organs, two groups known as the M1 classification according to the 9 Results: CLM developed in 125 cases. Eighty-one individuals had contralateral metastases at diagnosis, and 44 developed CLM during follow-up. Distant metastases were present in 100 patients; there was no CLM in the control group. While there was no statistical difference between the two groups in terms of the SUV Conclusion: The study emphasized the role of ipsilateral nodules, pleural effusion, and pleural metastasis in predicting CLM using

Indexed as

18F-FDG PET/CTcontralateral lung metastasiscontralateral spreadlung cancerpleural spread

Identifiers

PMID41058143
PMCPMC12505199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.